In the Margins
French pharmaceutical company Sanofi said it will seek to replace the board of Medivation after the American drug maker’s directors rejected a $9.3 billion takeover offer. Sanofi said in April that Medivation’s directors had failed to respond to its approach. Meanwhile, Medivation’s board called the offer “inadequate,” and founder and CEO David Hung has said the French company’s move was “opportunistically timed.” Read the original story from The New York Times.
Most Read
Mutual fund industry veteran Frank Nasta, who retired from JPMorgan's U.S. funds business in mid-2018, is among three new independents nominated to join the Federated Hermes ...
Building and maintaining a diverse membership has become a top priority for many mutual fund boards in recent years, and new data shows this focus is ...
Total compensation paid to independent mutual fund directors in 2023 increased, though the difference was smaller than in the year prior, according to industry data obtained ...
The Putnam Funds board has new leadership and a new independent member following the retirement of Kenneth Leibler, who chaired the board for six years and ...